151 related articles for article (PubMed ID: 28552062)
1. Discovery of Chromen-7-yl Furan-2-Carboxylate as a Potent and Selective Factor XIa Inhibitor.
Obaidullah AJ; Al-Horani RA
Cardiovasc Hematol Agents Med Chem; 2017 Nov; 15(1):40-48. PubMed ID: 28552062
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212).
Pinto DJP; Orwat MJ; Smith LM; Quan ML; Lam PYS; Rossi KA; Apedo A; Bozarth JM; Wu Y; Zheng JJ; Xin B; Toussaint N; Stetsko P; Gudmundsson O; Maxwell B; Crain EJ; Wong PC; Lou Z; Harper TW; Chacko SA; Myers JE; Sheriff S; Zhang H; Hou X; Mathur A; Seiffert DA; Wexler RR; Luettgen JM; Ewing WR
J Med Chem; 2017 Dec; 60(23):9703-9723. PubMed ID: 29077405
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Benzyl Tetraphosphonate Derivative as Inhibitor of Human Factor Xia.
Kar S; Mottamal M; Al-Horani RA
ChemistryOpen; 2020 Nov; 9(11):1161-1172. PubMed ID: 33204588
[TBL] [Abstract][Full Text] [Related]
4. Sulfonated non-saccharide molecules and human factor XIa: Enzyme inhibition and computational studies.
Al-Horani RA; Parsaeian E; Mohammad M; Mottamal M
Chem Biol Drug Des; 2022 Jul; 100(1):64-79. PubMed ID: 35377529
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of novel proline based factor XIa selective inhibitors as leads for potential new anticoagulants.
Hussain Z; Cooke AJ; Neelamkavil S; Brown L; Carswell E; Geissler WM; Guo Z; Hawes B; Kelly TM; Kiyoi Y; Lai K; Lesburg C; Pow E; Zang Y; Wood HB; Edmondson SD; Liu W
Bioorg Med Chem Lett; 2020 Aug; 30(16):127072. PubMed ID: 32340773
[TBL] [Abstract][Full Text] [Related]
6. Fragment-Based Lead Generation of 5-Phenyl-1
Wei Q; Zheng Z; Zhang S; Zheng X; Meng F; Yuan J; Xu Y; Huang C
Molecules; 2018 Aug; 23(8):. PubMed ID: 30103465
[TBL] [Abstract][Full Text] [Related]
7. A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding.
Al-Horani RA; Abdelfadiel EI; Afosah DK; Morla S; Sistla JC; Mohammed B; Martin EJ; Sakagami M; Brophy DF; Desai UR
J Thromb Haemost; 2019 Dec; 17(12):2110-2122. PubMed ID: 31397071
[TBL] [Abstract][Full Text] [Related]
8. Allosteric inhibition of human factor XIa: discovery of monosulfated benzofurans as a class of promising inhibitors.
Argade MD; Mehta AY; Sarkar A; Desai UR
J Med Chem; 2014 Apr; 57(8):3559-69. PubMed ID: 24666186
[TBL] [Abstract][Full Text] [Related]
9. Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants.
Al-Horani RA; Gailani D; Desai UR
Thromb Res; 2015 Aug; 136(2):379-87. PubMed ID: 25935648
[TBL] [Abstract][Full Text] [Related]
10. Factor XIa Inhibitors as New Anticoagulants.
Quan ML; Pinto DJP; Smallheer JM; Ewing WR; Rossi KA; Luettgen JM; Seiffert DA; Wexler RR
J Med Chem; 2018 Sep; 61(17):7425-7447. PubMed ID: 29775297
[TBL] [Abstract][Full Text] [Related]
11. Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group.
Corte JR; Fang T; Pinto DJ; Orwat MJ; Rendina AR; Luettgen JM; Rossi KA; Wei A; Ramamurthy V; Myers JE; Sheriff S; Narayanan R; Harper TW; Zheng JJ; Li YX; Seiffert DA; Wexler RR; Quan ML
Bioorg Med Chem; 2016 May; 24(10):2257-72. PubMed ID: 27073051
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
[TBL] [Abstract][Full Text] [Related]
13. Fasxiator, a novel factor XIa inhibitor from snake venom, and its site-specific mutagenesis to improve potency and selectivity.
Chen W; Carvalho LP; Chan MY; Kini RM; Kang TS
J Thromb Haemost; 2015 Feb; 13(2):248-61. PubMed ID: 25418421
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of macrocyclic indoles targeting blood coagulation cascade Factor XIa.
Hanessian S; Larsson A; Fex T; Knecht W; Blomberg N
Bioorg Med Chem Lett; 2010 Dec; 20(23):6925-8. PubMed ID: 21035339
[TBL] [Abstract][Full Text] [Related]
15. Development of Selective FXIa Inhibitors Based on Cyclic Peptides and Their Application for Safe Anticoagulation.
Carle V; Wu Y; Mukherjee R; Kong XD; Rogg C; Laurent Q; Cecere E; Villequey C; Konakalla MS; Maric T; Lamers C; Díaz-Perlas C; Butler K; Goto J; Stegmayr B; Heinis C
J Med Chem; 2021 May; 64(10):6802-6813. PubMed ID: 33974422
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the discovery and development of factor XI/XIa inhibitors.
Al-Horani RA; Afosah DK
Med Res Rev; 2018 Sep; 38(6):1974-2023. PubMed ID: 29727017
[TBL] [Abstract][Full Text] [Related]
17. Factor XIa inhibitors: A review of the patent literature.
Al-Horani RA; Desai UR
Expert Opin Ther Pat; 2016; 26(3):323-45. PubMed ID: 26881476
[TBL] [Abstract][Full Text] [Related]
18. Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa.
Al-Horani RA; Ponnusamy P; Mehta AY; Gailani D; Desai UR
J Med Chem; 2013 Feb; 56(3):867-78. PubMed ID: 23316863
[TBL] [Abstract][Full Text] [Related]
19. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Wong PC; Jiang X
Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
[TBL] [Abstract][Full Text] [Related]
20. Structural Basis for Activity and Specificity of an Anticoagulant Anti-FXIa Monoclonal Antibody and a Reversal Agent.
Ely LK; Lolicato M; David T; Lowe K; Kim YC; Samuel D; Bessette P; Garcia JL; Mikita T; Minor DL; Coughlin SR
Structure; 2018 Feb; 26(2):187-198.e4. PubMed ID: 29336885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
